Search Results

You are looking at 111 - 120 of 167 items for :

  • "BRAF mutation" x
  • Refine by Access: All x
Clear All
Full access

Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton

.3, C18.4), left (C18.5, C18.6, C18.7), or colon not otherwise specified (C18.8, C18.9); tumor grade; tumor stage; MSI status; and KRAS and BRAF mutation status. Information about perforation was abstracted from operative reports, pathology reports

Full access

Christopher A. Barker and April K. Salama

. “As I mentioned, genomic testing is predictive in cutaneous melanoma. For instance, the BRAF mutation is a predictor of response to RAF inhibition. In addition, the overall number of mutations seen in cutaneous melanoma may be a predictor of the

Full access

Heather Hampel

the “second hit” in a patient with a germline MLH1 mutation, and therefore a positive methylation test does not rule out a germline MLH1 mutation completely. Finally, tumor DNA can be tested for the somatic BRAF mutation V600E. This mutation is

Full access

Olumide Gbolahan, Neda Hashemi-Sadraei, and Bert O’Neil

, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel . Cancer 2009 ; 115 : 760 – 769 . 19127559 10.1002/cncr.24019 24. Gras E , Catasus L , Argüelles R , . Microsatellite

Full access

Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss

, de Gramont A , Vernerey D , . Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study . J Clin Oncol

Full access

Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman

young adults aged 17 to 35 years with glioblastomas found a more favorable overall survival among those with BRAF mutations than those without. 26 Another retrospective review of PXAs also found a more favorable overall survival associated with BRAF

Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

blood was sent for analysis of circulating tumor DNA (ctDNA) by Guardant360 (Guardant Health, Inc.), revealing the known BRAF mutation with a variant allele frequency (VAF) of 28% and a KRAS p.Q61K mutation with a low VAF of 0.2%, as well as

Full access

Jaideep Sandhu, Chongkai Wang, and Marwan Fakih

-sided CRC and are uncommon in the setting of KRAS , NRAS , and BRAF mutations. 5 – 7 Although the prognostic role of HER2 amplification in metastatic CRC (mCRC) is unclear, studies have highlighted it as a therapeutic target. 1 , 3 , 8 In addition

Full access

Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H.L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, and Heather H. Cheng

, such as ROS1 mutations in lung cancer 1 and BRAF mutations in melanoma. 2 In addition, the clinical applications of germline sequencing in solid tumors have rapidly expanded. 3 – 6 Thus, NGS is a powerful tool that can potentially provide an

Full access

Jacob Strelnikov, Alice Zhou, Omar Butt, Michael Ansstas, and George Ansstas

– 1720 . 3. El-Osta H , Falchook G , Tsimberidou A , BRAF mutations in advanced cancers: clinical characteristics and outcomes . PLoS One 2011 ; 6 : e25806 . 4. Davies MA , Liu P , McIntyre S , Prognostic factors for survival